Rifabutin Use in Staphylococcus Biofilm Infections: A Case Series

Antibiotics

Afua Ntem-Mensah¹  PatrickR. Ching²  EmilyL. Heil³  Renaldo Neeley⁴  JamesB. Doub⁴ 

[1] Department of Infectious Disease, Faith Regional Health Services, Norfolk, NE 68701, USA;Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, MD 21201, USA;Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA;Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, MD 21201, USA;

关键词: biofilms;    rifabutin;    Staphylococcus;    drug interactions;    periprosthetic joint infection;   

DOI  :  10.3390/antibiotics9060326

来源: DOAJ

【 摘 要 】

This is a case series of 10 patients who had staphylococcal biofilm infections that were treated with adjuvant rifabutin therapy instead of rifampin therapy. In these cases, rifampin was contraindicated secondary to drug–drug interactions with the patients’ chronic medications. Rifabutin therapy was well tolerated with no side effects. As well, no patients had recurrence of their staphylococcal infections. This case series shows that rifabutin can be a beneficial adjuvant therapy in Staphylococcus biofilm infections when drug–drug interactions limit the use of rifampin.

【 授权许可】

Unknown